

ANNUAL REPORT

Our mission is to end breast cancer through the power of action and advocacy.

NECC



NCEF

A MESSAGE FROM THE PRESIDENT

It is an honor to be part of this incredible coalition and to benefit firsthand from the resilience and dedication of our grassroots advocates, volunteer scientists, and committed donors. These stakeholders helped us make great progress in 2022 on our agenda to end breast cancer. And yet, at the same time, we lost thousands of women and men, including some of NBCC's longtime leaders. Those losses are keenly felt and fuel our passion for our mission. We continue our work to protect future generations from breast cancer.

Our mission is, and always has been, to end breast cancer. That is the basis of the work we did in 2022 and will be our bedrock moving forward. We do not just say those words, we remain relentlessly committed to this work.

As you will see in this report, we continue to expand our education and training programs to reach advocates nationwide and globally. This year, our advocacy work was recognized by the American Association for Cancer Research, one of the largest science associations in the world. We continue to be a powerful voice for patients in the global science arena, especially through our clinical trials work. We again successfully secured an additional \$150 million in research funding for the Department of Defense peer-reviewed Breast Cancer Research Program, and our trained advocates continued to influence how those research funds were allocated.

We expanded our Artemis Project to include new scientists and advocates, forming new research collaborations among participants that will save lives. As the Artemis preventive vaccine continued to move closer to a Phase 1 clinical trial, we began a strategic plan to institutionalize Artemis as a virtual collaboration entity, to preserve the long-term viability of this unprecedented science project.

As you may know, our work is complex, difficult, and very necessary. Your support of that work is vital to our success. I hope you find the summary of our work in 2022 compelling, and trust that your gifts are making a difference for hundreds of thousands of women and men today as well as for future generations.

'Frances M. Visco President, National Breast Cancer Coalition





Our mission is to end breast cancer through the power of action and advocacy. NBCC has two arms: NBCCF, a 501 C(3) entity that educates and trains advocates

to understand the language and concepts of science; collaborates with scientists and conducts research programs to advance an innovative agenda and influences the health care system to ensure access to quality care. Our 501 (c)(4) arm sets a public policy agenda and works to enact the necessary legislation, policy, and regulation to end breast cancer. This arm lobbies through its grassroots network for increased research funding, access to care, and expanded advocate involvement. Together, these two arms underpin our strategic approach to ending breast cancer.

based

RESEARCH

NBCC works to increase the effectiveness of breast cancer research in several ways.

Research Collaborations



NBCC leads collaborations that change the systems of research. Through our Artemis Project[®], an innovative, mission-driven collaboration of advocates and scientists, we identify and answer the questions vital to ending breast cancer. Artemis focuses on Primary Prevention — how to stop women and men

from getting breast cancer — and the Prevention of Metastasis — how to stop breast cancer from becoming lethal.

In March 2022, NBCC hosted its annual Artemis Project meeting, bringing together participants to develop plans of action to advance work on Artemis goals. The meeting on primary prevention culminated in research work plans related to localized therapies for risk reduction, strategies for improving risk prediction, and engineering an antibreast cancer immune system. On preventing metastasis, the group catalyzed ideas about how to induce better immunity in primary tumors, how to potentially mobilize and destroy dormant disseminated tumor cells, and how to make disseminated tumor cells more immunogenic. Throughout the year, participants engaged in webinars and conference calls to refine plans, provide additional input, and evaluate possible new focus areas.

- Primary Prevention The initial project undertaken by Artemis was to develop a safe and cost-effective vaccine targeting all three major subsets of breast cancer to reduce incidence and prevent death. NBCC continued to advance our preventive vaccine, which targets all major subsets of breast cancer, in partnership with the NCI Prevent program. (The NCI PREVENT Program supports, in their words, the best in cancer prevention that addresses unmet needs not adequately addressed by the private sector.) We now expect to launch a Phase 1 trial in 2023. NBCC filed for a provisional patent on the vaccine so that if it works, we can help ensure it is affordable and accessible globally.
- Prevention of Metastasis Artemis participants initially focused on tumor dormancy and specifically whether the immune system interacts with dormant, disseminated tumor cells (DTCs) and how to intervene to stop them from becoming lethal. Independent of Artemis, several participants formed collaborations to advance ideas developed at Artemis, leveraging the project's reach.

Clinical Trials

NBCC continued its collaboration with Translational Research In Oncology (TRIO) and Novartis on a clinical trial of CDK4/6 inhibitors in early high-risk HR+ breast cancer, the NATALEE trial. NBCC participates on the trial Steering Committee, the data safety monitoring board, and the translational research committee.

With these scientific-community collaborations, NBCC works to develop new research models, conduct research, design protocols, set research priorities and conduct research aimed at ending breast cancer.

OUTREACH

NBCC presented at or attended several national meetings on the issues of clinical trial research, patient advocate involvement in clinical trials, and research efforts. These included the ASCO Annual Meeting, the Cancer Research UK Grand Challenge Summit, the Integration Panel of the Department of Defense Breast Cancer Research Program, the National Cancer Reporting Fellowship training hosted by the Association of Healthcare Journalism, the NCI Council for Research Advocates meeting, and the San Antonio Breast Cancer Symposium.

As a grassroots organization, NBCC recognizes the importance of an empowered public and provides the public with evidence- based and patientcentered information on important breast cancer issues and research.

As part of that work, we publish Science Spotlights which provide in-depth analyses of recently published breast cancer research, the results of pivotal breast cancer clinical trials, and other newsworthy breast cancer information. In 2022, NBCC published seven articles discussing key research presented at major conferences, as well as features on new drug approvals in breast cancer.



EDUCATION AND TRAINING

NBCC's organizational mandate is to train and develop a strong, knowledgeable nationwide network of breast cancer advocates.

NBCC knows that we will only end breast cancer if trained, educated advocates play a leadership role in getting there. Our education and training programs are designed to empower advocates by teaching them the complexities of breast cancer science, research, and the public policy process to ensure their voice is not only heard but provokes system change.



Project LEAD[®] **Institute** — NBCC hosted two, inperson sessions of the Project LEAD Institute where we educated more than 60 advocates from across the country, and around the globe, in breast cancer biology and genetics, epidemiology, immunology, and clinical trial design.

Advanced Project LEAD — Advanced Project LEAD advocates participated in an exclusive webinar with Dr. Steven Vogl on the current state of cancer research and medical care in the United States and across the globe. Additionally, a Breast Cancer Models project, driven by a group of Advanced LEAD advocates, continues to make progress. To aid advocates in understanding what models are used in cancer research and why, this project is developing a hierarchy of models, a glossary of terms, and a comprehensive white paper based on literature reviews and interviews with breast cancer researchers.

Continuing Education – NBCC conducted numerous webinars on various topics, including two multi-part series on critical appraisal and the demystification of IRBs, among others. NBCC also hosted two in-person Advanced Topic Sessions for Project LEAD graduates: "Application of Advanced Technologies Like CRISPR in Breast Cancer Research" and "The Future of HER2 Low Breast Cancer."

Learning Management System (LMS) – NBCC's online education portal completed pilot testing and will roll out to a broader advocate user base in 2023. Current programming consists of seven education modules, including clinical trial methodology, patient-reported outcomes and measurements, ethical issues in clinical trial conduct, and the use of models in breast cancer research. The creation of new learning modules is ongoing.

Advocate Leadership Summit — More than 120 dedicated NBCC advocates attended NBCC's Advocate Leadership Summit in Washington, D.C., the first to be held in person since 2019. Session topics included "Getting to Value-Based Cancer Care," "Breast Cancer Disparities: Advancing Health Equity in Cancer Care," "New Horizons in Cancer Metastasis Research," "Congress 101: Navigating Capitol Hill for Advocates," "Advocacy When the House is On Fire: How Grassroots Organizations can Save Democracy and Still Accomplish their Goals," and an update on the work of NBCC's Artemis Project. The program also included remarks from U.S. Representative Jamie Raskin and a Q&A session with NBCC President Fran Visco.

PUBLIC POLICY

The NBCC Board of Directors establishes NBCC's legislative and public policy priorities each year. In 2022, NBCC made significant progress on its priorities.

- Annual Membership Lobby Day Advocates held more than 200 meetings with their members of Congress to push for the adoption of NBCC legislative priorities. In home districts, advocates attended virtual town halls and published letters to the editor in local papers to advocate for NBCC priorities.
- Team Leader Training NBCC maintains a network of Team Leaders who are trained to lead advocates throughout the year in advancing our Policy agenda. During the virtual 2022 Team Leader Training, NBCC educated Team Leaders on how Congress works, committee structure and process, regulatory process, strategic approaches to developing a policy agenda, communicating effectively with policymakers, how to grow an advocacy network, and other relevant topics. NBCC Team Leaders participated in monthly Zoom meetings to stay updated on legislative and public policy priorities.
 - Breast Cancer Caucus NBCC's Breast Cancer Caucus educates voters and candidates that breast cancer is a political issue. The Breast Cancer Caucus raises awareness and support for NBCC's public policy priorities through voter and candidate education and get-out-the-vote activities. In 2022 the Breast Cancer Caucus engaged mid-term voters via a campaign where NBCC advocates sent Caucus branded GOTV postcards to their networks of family and friends, positioning breast cancer as an issue influencing voters in the mid-term elections.

Legislative Priorities:

- DOD Breast Cancer Research Program In 1992, the Department of Defense Breast Cancer Research Program (DOD BCRP) started because of NBCC's campaign to increase federal appropriations for breast cancer research. Through NBCC's advocacy work, Congress approved \$150 million in FY23.
- Metastatic Breast Cancer Access to Care Act— NBCC's advocates were responsible for obtaining strong bipartisan support for our priority legislation, S. 1312/H.R. 3183, the Metastatic Breast Cancer Access to Care Act, which NBCC initiated. This bill waives Social Security and Medicare waiting periods for people living with metastatic breast cancer.
- Preservation of the Medicaid Breast and Cervical Cancer Treatment Program — Congress enacted the Breast and Cervical Cancer Treatment Act in 2000 after years of NBCC grassroots lobbying and influence. NBCC remains committed to ensuring all women and men screened and diagnosed with breast cancer have access to the treatment they need.

At the end of the 117th Congress in 2022, NBCC advocacy resulted in 240 bipartisan cosponsors in the House and 29 in the Senate. NBCC advocates engaged in intense end-of-year advocacy aimed at having this legislation attached to the omnibus spending package.

While that effort was unsuccessful, NBCC raised awareness and created strong momentum for enactment in the 118th Congress in 2023.

Public Policy Priorities:

NBCC develops public policy priorities to advance non-legislative issues that are important to ending breast cancer. NBCC evaluates laws and regulations against these policies, and takes appropriate action when needed.

Guaranteed Access to Quality Care for All – NBCC supports health care access initiatives that expand access to Medicare while also offering a private insurance option, automatically enrolling individuals who do not have access to other coverage, and providing guaranteed benefits including primary and preventative care, hospital services, and prescription drug coverage.

Access to Affordable & Effective Therapies — NBCC supports policies that address systemic deficiencies in the law, regulation, and science policy resulting in drug approvals that do not significantly extend or save lives and whose prices are not based on value or effectiveness based on Board adopted principles.

Educated Patient Advocate Participation — NBCC continues to work to ensure that educated patient advocates who represent a constituency have a meaningful seat at the table in all levels of health care and breast cancer decision-making.



SPECIAL EVENTS

Les Girls


NBCC's signature fundraising event, Les Girls Cabaret, was held at Paramount Studios on October 23rd 2022. The event included celebrity appearances from Jennifer Coolidge and performances from Merle Dandridge, Chris Gorham, and Marilu Henner. The 2022 event raised a record breaking amount and was full of fun, song and celebration.

NYC Women With Balls®

The New York Women With Balls bowling event was held in person on 10/17 at Frames NYC. NBCCF Board member Liane Martins Lindner continued to serve as our Event Chair. This unique event offers a fun opportunity for people to raise funds to support NBCC. It continues to grow in popularity and raised the most in its 5-year history in 2022.

YOUR DOLLARS AT WORK

2022 Expenses \$ 3,665,990*



* Pie-chart reflects expenses of \$3,489,180
It does not include event related direct benefits to donors of \$176,810

Assets 2022

Cash & Cash Equivalents	\$4,477,387
Accounts Receivables	\$1,288,287
Prepaid Expenses	\$178,046
Net Property & Equipment	\$21,652
Deposits	_
TOTAL ASSETS	\$5,965,372
LIABILITIES	\$177,782
TOTAL NET ASSETS	\$5,787,590
TOTAL LIABILITIES & ASSETS	\$ 5,965,372

2022 Public Support & Other Revenue \$4,741,148*

2% Other Revenue, \$96,319	
10.3% Corporation & Foundations, \$488,094	
51.8% Restricted Grants, \$2,456,112	
14.5% Special Events, \$688,572	
21.4% Individuals, \$1,012,050	

 Total Expense and Total Revenue include event costs that are direct benefits to donors, \$176,810.

2022 BOARD OF DIRECTORS

ABCD: After Breast Cancer Diagnosis Bonnie Anderson (D) Linda Hansen (A)

Alamo Breast Cancer Foundation Jerry Worden (D) Beth Emery (A)

American Association of Breast Care Professionals Rhonda Turner (D) Gretchen Walton (A)

Annie Appleseed Project Ann Fonfa (D) Rasheedah Ahmad (A)

Breast Cancer Care and Research Fund Michele Rakoff (D) Michele Atlan (A)

CARE Advocates Network Carol Matyka (D) Karen Poliseno (A)

Cedar Valley Cancer Committee: Beyond Pink TEAM Christine Carpenter (D) Lori Seawel (A)

Cedars Sinai Breast Center Sherry Goldman (D) Sylvia Estrada (A)

Delaware Breast Cancer Coalition, Inc. Francesca Vogel(D) Susan Murray (A)

Dr. Susan Love Research Foundation Judi Hirshfield-Bartek (D) Christopher Clinton Conway (A) Florida Breast Cancer Foundation

Valencia Robinson (D) Judy Perkins (A)

Lobular Breast Cancer Alliance Laurie Hutcheson (D) Mason Mitchell-Daniels (A)

Metropolitan Washington, DC Chapter of NBCC Tania Chomiak-Salvi (D) Wanda Lucas (A)

Michigan Breast Cancer Coalition Rose Marie Sitko (D) Jeanne Deneweth (A)

Minnesota Breast Cancer Coalition Christine Norton (D) Pat Haugen (A)

National Breast Cancer Coalition Frances M. Visco (D)

Nueva Vida Astrid Jiménez, Esq. (D) Gloria Elliott (A)

SHARE Jennie Santiago (D) Stephanie Poland (A)

Virginia Breast Cancer Foundation Marylinn Minor (D) Katy Sawyer (A)

Young Survival Coalition Joy Simha (D)

A = Alternate

National Breast Cancer Coalition Fund 2022 BOARD OF TRUSTEES

Alec R. Call Beth Emery, JD Sherry Goldman RN, NP, MSN Ira Hillman, Treasurer Judi Hirshfield-Bartek, RN, MS, OCN Bryan Johns Liane Martins Lindner, Chair Christine Norton, MA, Secretary Michele Rakoff Linda Rothweiler, DMD, Vice Chair Dennis Slamon, MD, PhD Frances M. Visco, JD Douglas Wall, MBA Ann C. Yahner, JD

In Memoriam: Carol Vance Wall

2022 DONORS

Corporations, Foundations and Donor Advised Funds

Amazon Smile Foundation Alan Sieroty Charitable Fund Angelo Family Charitable Fund Arizona Gatorade Boys Cross Country Barbara Silver Levin Foundation **Bessemer Trust** Beth Sieroty Meltzer Fund **Bisceglio Fernandez Fund Boston Foundation** Broad Survivors Trust Brown Rudnick Cardoso Family Foundation Cedar Valley Cancer Committee: Beyond Pink TEAM Cedars Sinai Breast Center Costigan Family Gift Fund Dermod and Christine Norton Family Charitable Fund Edward Jones Charitable Gift Fund Eisenberg, Rothweiler, Winkler, Eisenberg & Jeck, P.C. Elm Street Foundation **Exact Sciences** Fitzgerald Giving Fund Forbes Family Charitable Account Gantswig-Welinsky Fund George and Amy Klette Newman Foundation Ira Hillman & Jeremy Barber Family Fund **iS CLINICAL by INNOVATIVE SKINCARE** James and Deborah Burrows Foundation

Jewish Federation of St. Louis Jill Grey Family Charitable Foundation Joyce and Irving Goldman Family Foundation JT Charitable Fund Judges & Lawyers Breast Cancer Alert Judy and Peter Blum Kovler Foundation Kretzman Family Charitable Fund Linda Creed Breast Cancer Organization Lloyd-Sorkin Charitable Trust Luis & Lee Lainer Fund Luling High School - Student Activity Fund Martin Gruber Fund Match Sanderson Foundation Maurice and Lena Russo Family Foundation May and Walt Family Charitable Fund Mellam Family Foundation Merck & Co., Inc. Michael Dunitz Crisis Foundation, Inc. Michele Asselin and J. Meltzer Fund Minnesota Breast Cancer Coalition Mueller Family Foundation Musa and Tom Mayer Charitable Fund National Philanthropic Trust National Sportsmanship Foundation Inc. Novartis Oncology Pfizer, Inc. **Progressive Jewish Fund** Purcell Fund

Quantbot Technologies, LP

R & L Donner Trust **Richard and Hinda Rosenthal Foundation** Richard and Suzanne Kayne Charitable Fund Riskified Rita J. & Stanley H. Kaplan Family Foundation, Inc. **RMF** Foundation Robert S. Fleischer and Susan L. Raanan Charitable Fund Roskam Family Giving Fund Safra National Bank Sandra Shorenstein & Gregory Kuhn Fund Schnader Harrison Segal & Lewis LLP Sevenwinds Casino, Lodge & Conference Center Stephen Moeller and Vivian Arias Charitable Fund Steve Tisch Family Foundation Suzanne H. Kaye Advocacy Fund Sylvan C. Coleman Trust The Alfred and Rosemary Iversen **Family Foundation** The Biondi Family Fund The David and Nancy Poorvu Charitable Trust The David Geffen Foundation The Foundation for Delaware County The Herbert McLaughlin Children's Trust The Horn Foundation The Jordan-Evans Family Foundation The Robert and Shirley Harris Family Foundation The Wonderful Company Foundation Translational Research in Oncology-US, Inc. (TRIO-US) TRIO Vance Wall Foundation VerSteeg & Pierson Giving Fund Williams Giving Fund Young Conaway Stargatt & Taylor, LLP



2022 DONORS

Individuals

Greater than \$1M

Carol* and Terry Wall

Gifts from \$500,000 to \$999,999

Dorian S. Goldman and Marvin Israelow Katja Goldman and Michael Sonnenfeldt Lloyd and Victoria Goldman

Gifts from \$250,000 to \$499,999

Alec Call and Bryan Johns

Gifts from \$100,000 to \$249,999

Musa and Tom Mayer

Gift from \$50,000 to \$99,999

Jennifer Coolidge Cindy and Alan Horn Linda Essakow and Stephen Gunther

Gifts from \$25,000 to \$49,999

Anne Andrews Rhett and Chelsey Reese Linda Rothweiler, DMD and Ken Rothweiler Ann C. Yahner Steve Tisch

Gifts from \$10,000 to \$24,999

Lachs Adler and Dean Adler James & Deborah Burrows Kate Dwyer Patricia L. Freysinger Judi Galst Pennelope Goodfriend Judy and Peter Kovler Peter Morton Melinda Nordeng Richard Pachulski Michele Rakoff and Alan Sieroty Arleen F. Sorkin* Fran M. Visco and Arthur N. Brandolph Arnold Levin Lynda and Stewart Resnick

Gifts from \$5,000 to \$9,999

Beth Emery Chester and Donna Call Blake T. Johns and Brittany Shaw Susan K. Johns Judy Dering and Frank Calzone Janet Kossman Stephen and Lina Wall Gerry Bernardi and Joe Keenan Edward Joyce and Linda Gerstel Hilary Newsom Daniel Holme and Lyman Goodrich Christine K. and Dermod Norton Laurentia Popa Ira Hillman and Jeremy Barber Cynthia Nicholson John Noss Glenn and Lynn Cardoso John and Emily Costigan Anonymous Sheri Disney Greg Essakow Steven and Jodie Fishman Silvia C. Formenti, MD and

Roger Spottiswoode Stan and Mary Friedman Henry and Arline Gluck Suzanne and Ric Kayne Diana Wendy and Hugh Kendrick Michele May and David R. Walt, PhD Arik Preis Abbie Lee and William G. Warden IV Martha Williams Kathy M. Ball

Gifts from \$1,000 to \$4,999

Ramesh and Sina Akhtarzad Madeline and Stephen Anbinder Holly M. Anderson Michael and Carla Angelo Alan Appelbaum Susan and Robert Appleton Michele Asselin and Joseph Meltzer Beau and Laura Avril Annette Bar-Cohen Allen Baum Susan Bay-Nimoy Joshua Beal Jennifer and Matthew Berzok Carol Biondi Isabelle T. Bisceglio, PhD Phillip and Nina Blumenfeld Carmella Bocchino Corlis Boggs Ruth and Peter Brooke Shirley H. Brown Joe Camardo, MD **Byron Capps** Christine B. and Delburn Carpenter **Richard Cassese**

Margaret Clarke Elaine M. Coughlin Jayanta Debnath, MD Maria Driscoll Donna M. Duncan Dale and Harry Eastman Paul Emerv **Carol Evans** Ileane and Irvin Fagin Kathleen Fernan Kathleen Fitzgerald Judy and Tom Flesh Sean Francis Elizabeth and Richard Frank Paula Freiburger Muriel L. Frischer, PhD Henry Furst Karren Ganstwig and Howard Welinsky Monah and Alan Gettner Caitlin and Cyrus Ghajar Patricia L. Glaser Jeri and David Glaser Carole Goldberg Jeffrey C. Golden Sherry and Barry Goldman George T. Grant Adam Greene Lisa & Joshua Greer Janet and Wayne Gretzky Jill Grey Lauren Gross Donald Grosset Martin Gruber Susan R. Hester Michele Hille Judi J. Hirshfield-Bartek and Elmer Bartek Roberta Holstein Keith Hurvitz. MD and Sara Hurvitz, MD Laurie Hutcheson Lonnie L. Israel Gail Israel Rosemary and Alfred W. lversen Harris S. Jaffe

Jeffrey Johns Gail Kamer Lieberfarb Dennis and Julie Kiraly Ethel Klein Caron Klein Scott and Melissa Klein Keith and Nancy Krakaur Robert K. Kretzman Gregory Kuhn Luis and Lee Lainer Meghan Landymore Deborah Laub Barbara E. Lazaroff Marva Lewis McKnight Karen and Franklin Lewkowitz Liane Martins Susan F. and James E. Lindsav Marie Lippman Nancy Lisagor, PhD Lawrence B. Ludwig H. Kim Lyerly, MD Ngina Lythcott, PhD and Byllye Avery Dennis Magrdichian Christopher Marin Joanne Marquardt Carol Matyka Mary Matyka Jacqueline McMullen Molly Mead Catherine M. Meek and Al Earle Beth Sieroty Meltzer Nikki and Joel Miliband Laura A. Miller Stephen Moeller and Vivian Arias Martha Moroney Pamela Morton Todd Nickey and Greg Holcomb Bill Nye Joshua and Laurie Olshansky Robin Ozerkis Lydia B. Parnes

Caroline Jett-Sun

James D. Parriott and Diane Carv Lori Petitti Karen Poliseno Nancy Poorvu Richard and Debbie Powell **Christopher Prendergast** Nancy and Coy Purcell Robert Fleischer and Susan Raanan Jay Race Jane Rascoff Pamela Romanow Janice Rosenhaus Skip and Marilyn Rosskam Rosemary Rosso Beth Rothschild Bernice Rudolph Rosemary Ruggiero Phoebe Scherer Helen Schiff and Richard Congress Helena Schwartz Gail and Steven Shak Sandra Shorenstein Lauren Shuler Donner **Robert Simmons** Dennis Slamon, MD and Obie Slamon Sherri Stahl Lisbeth Tarlow Gomer Thomas Katherine Tobin Michelle and Stephen Tregear Amedeo Ursini John VerSteeg and Jane Pierson Gary and Elizabeth Wohl Melanie Wyne Carol Zipkin Earle

Bequests

Beatrice Lemlein* Gary Ponali* Elaine Soter*

*deceased



2001 L Street, NW Suite 500 PMB #50111 Washington, DC 20036

(202) 296-7477 www.stopbreastcancer.org

The National Breast Cancer Coalition Fund is the 501 (c)(3) arm of NBCC that designs and runs programs to educate, train, and inform advocates, policymakers, scientists, providers, and the public about breast cancer science, health care and advocacy. The Fund collaborates with the research community on innovative research, effects change in the health care system to advance access to quality health care for all, and gives a powerful, effective voice to breast cancer advocates everywhere.

The National Breast Cancer Coalition, NBCC's 501 (c)(4) arm, sets a public policy agenda and then works to enact the necessary legislation, policy, and regulation to end breast cancer. The Coalition lobbies through its grassroots network for increased funding for innovative research, a seat at the table to oversee how those funds are spent, and public policies to expand access to quality health care for all.